

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/763,617	06/11/2001	Klaus Wanner	P20670	6673
7055 7:	590 05/05/2004		EXAMINER	
GREENBLUM & BERNSTEIN, P.L.C.			SHAMEEM, GOLAM M	
1950 ROLAND CLARKE PLACE RESTON, VA 20191			ART UNIT	PAPER NUMBER
1001011, 771	20171	•	1626	
			DATE MAILED: 05/05/200	4

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Comment	09/763,617	WANNER ET AL.				
Office Action Summary	Examiner	Art Unit				
	Golam M M Shameem	1626				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠ Responsive to communication(s) filed on <u>11 August 2003</u> .						
	·					
•—	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) 31-61 is/are pending in the application 4a) Of the above claim(s) is/are withdrated 5) Claim(s) is/are allowed. 6) Claim(s) 31-61 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or are subject to restriction and/or are subject to restriction and/or are subject to by the Examination of the specification is objected to by the Examination of the specification are subject to by the Examination of the specification are subjected to be subjected to by the Examination of the specification are subjected to by the Examination of the specification are subjected to be subje	er. cepted or b) objected to by the edrawing(s) be held in abeyance. Secondary	e 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:					

Application/Control Number: 09/763,617

Art Unit: 1626

DETAILED ACTION

Status of Claims

Claims 31-61 are pending in the application.

Receipt is acknowledged of Applicant's appeal brief filed on August 11, 2003 and that has been entered.

In an appeal conference, after review of issues presented it is decided to issue another non-final rejection based on primary reference of record. Therefore, the finality in the previous Office action (01/10/03) is hereby withdrawn and Applicant's arguments / response are rendered moot in view of the present Office action.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a), which forms the basis for all obviousness rejections, set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 31-61 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bondinell et al (US Pat No 4,514,414).

Applicant claims the compounds of formula (I) that are useful as GABA uptake inhibitors.

Determination of the scope and content of the prior art (MPEP §2141.01)

Bondinell '414 teaches analogous compounds as instantly claimed and their use as GABA uptake inhibitors.

Ascertainment of the difference between the prior art and the claims (MPEP §2141.02)

Application/Control Number: 09/763,617

Art Unit: 1626

Bondinell '414 teaches structurally similar compounds of the instantly claimed compounds wherein a pyrrolidinyl compound is substituted with the same N-A²Z and A¹X on the pyrrolidine ring. The difference between the instant claims and Bondinell '414 is that instead of 2- A¹X, Bondinell has 3- A¹X i.e. positional isomers.

Finding of prima facie obviousness--rational and motivation (MPEP §2142-2413)

One having ordinary skill in the art would consider the instantly claimed positional isomers of Bondinell '414 prima facie obvious because chemical compound, which is isomeric with compounds of prior art, is not patentable where new compound is not shown to possess new and unexpected utilities. See *In re Norris 84 USPQ 458 (1950)*, *In re Mehta 146 USPQ 284 (1965)*. In the instant case, one skilled in the art would be motivated to choose a positional isomer (that is substitution at 2-position on the ring carbon instead of 3-position on the ring carbon) in view of the known teaching in the field. Thus one ordinary skill in the GABA inhibitor art would be motivated to employ the prima facie structural variation of positional isomers in modifying Bondinell '414 since one would have reasonable expectation that such isomerism would give compounds with similar GABA uptake inhibitory activity.

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Golam Shameem, Ph.D. whose telephone number is (571) 272-0706. The examiner can normally be reached on Monday-Thursday from 6:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane, can be reached at (571) 272-0699. The Unofficial fax phone number for this Group is (703) 308-7921. The Official fax phone numbers for this Group are (703) 308-4556 or 305-3592.

Application/Control Number: 09/763,617

Art Unit: 1626

When filing a FAX in Technology Center 1600, please indicate in the Header (upper right) "Official" for papers that are to be entered into the file, and "Unofficial" for draft documents and other communications with the PTO that are not for entry into the file of the

application. This will expedite processing of your papers.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [joseph.mcKane@uspto.gov]. All Internet e-mail communications will be made of record in the application file. PTO employees will not communicate with applicant via Internet e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive data could be identified unless there is of record an express waiver of the confidentiality requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (571) 272-1600.

Golam M M Shameem, Ph.D.

amelm

Patent Examiner

Art Unit 1626, Group 1600

Technology Center 1

April 28, 2004